<DOC>
	<DOC>NCT00802542</DOC>
	<brief_summary>The purpose of this study is to prove in practice the effectiveness of Atacand 16 mg in reducing blood pressure after 4 weeks of administration and the importance of administration of adequate doses</brief_summary>
	<brief_title>In-practice Evaluation of Atacand 16mg Antihypertensive Effect</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<criteria>Adult patients with mild (140159/9099 mgHg) to moderate (160179/100109 mmHg) essential hypertension, already treated with Atacand 8mg for 24 weeks, who have not reached the blood pressure treatment goal at least &lt;140/90 mgHg and the doctor has decided Signed and dated Patient Informed Consent (ICF) Hypersensitivity to the active substance or to any of the excipients of Atacand.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>blood pressure</keyword>
	<keyword>Atacand</keyword>
</DOC>